ReviewJHEP reports : innovation in hepatology2021
Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past.
Review in JHEP reports : innovation in hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- The Association Between Telomere Length and Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Current molecular medicine · 2026Pooled it
- The dynamic spectrum of steatotic liver disease: the global perspective.Nature reviews. Gastroenterology & hepatology · 2026Review
- Current management of MASLD in type 2 diabetes.Hormones (Athens, Greece) · 2026Review
- Metabolic dysfunction-associated steatotic liver disease (MASLD): definition, diagnosis, natural history, and treatment.Japanese journal of radiology · 2026Review
- MetALD: decoding the evolution of steatotic liver disease nomenclature and implications for clinical practice and beyond.Gastroenterology report · 2026Review
- Cultural and Molecular Factors Predisposed to Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.Nutrients · 2025Review
- Association between the NHHR and hepatic steatosis and liver fibrosis: a population-based study.Scientific reports · 2025Article
- M6A methyltransferase METTL3 promotes glucose metabolism hub gene expression and induces metabolic dysfunction-associated steatotic liver disease (MASLD).BMC genomics · 2025Article
- Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective.Lipids in health and disease · 2025Review
- Hepatic steatosis: Qualitative and quantitative sonographic assessment in comparison to histology.Australasian journal of ultrasound in medicine · 2024Article
- Starvation-resistant cavefish reveal conserved mechanisms of starvation-induced hepatic lipotoxicity.Life science alliance · 2024Article
- Barriers to Exercise in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Patient Survey.Journal of clinical medicine research · 2024Article
- Therapeutic management of metabolic dysfunction associated steatotic liver disease.United European gastroenterology journal · 2024Review
- Sestrin2 maintains hepatic immune homeostasis and redox balance partially via inhibiting RIPK3-mediated necroptosis in metabolic dysfunction-associated steatohepatitis.Molecular metabolism · 2024Article
- Chronic Liver Diseases: What is Up?Journal of clinical medicine · 2024Article
- Starvation resistant cavefish reveal conserved mechanisms of starvation-induced hepatic lipotoxicity.bioRxiv : the preprint server for biology · 2024Article
- Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease.Gastro hep advances · 2024Article
- Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.Gastroenterology report · 2024Review
- Towards precision medicine in non-alcoholic fatty liver disease.Reviews in endocrine & metabolic disorders · 2023Review
- C-C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease.JHEP reports : innovation in hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder worldwide. This historical narrative traces the evolution from basic descriptions of fatty liver in the nineteenth century to our contemporary understanding of NAFLD in the twentieth and twenty-first centuries. A detailed historiographic review of fatty liver from 1800s onwards was performed alongside a brief review of contemporary associations. Archived published literature dating back to the 1800s describe clinicopathological features of fatty liver. In the nineteenth century, doyens of medicine associated fatty liver with alcohol, malnutrition or wasting conditions, and subsequently adiposity, unhealthy diets and sedentary lifestyle. Microscopically, fatty liver was described when 5% or more hepatocytes were distended with fat. Recommendations to reverse fatty liver included reducing consumption of fat, sugar, starchy carbohydrates and alcohol, plus increasing physical exercise. Fatty liver was associated with liver fibrosis and cirrhosis in the late 1800s, and with diabetes in the early 1900s. The diagnostic labels NAFLD and non-alcoholic steatohepatitis (NASH) were introduced in the late 1900s. Metabolic dysfunction-associated fatty liver disease (MAFLD) was recently proposed to update the nosology of fatty liver, recognising the similar metabolic pathogenesis evident in individuals with typical NAFLD and those with heterogenous "secondary" co-factors including alcohol and other aetiologies. Fatty liver has emerged from being considered a disorder of nutritional extremes or alcohol excess to contemporary recognition as a complex metabolic disorder that risks progression to cirrhosis and hepatocellular carcinoma. The increasing prevalence of NAFLD and our growing understanding of its lifestyle and metabolic determinants justify the current exercise of re-examining the evolution of this common metabolic disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.